What is Loopworm?
Founded in 2019 by Ankit Alok Bagaria and Abhi Gawri, Loopworm specializes in the conversion of organic waste into high-value insect-derived proteins and fats. While the company initially established its market presence by supplying sustainable ingredients for the aquaculture and pet nutrition industries, it has since pivoted toward a more complex technological frontier. Loopworm is currently pioneering a novel, reactor-free recombinant protein production platform that utilizes silkworms as living biological factories. This innovative approach effectively bypasses the traditional, resource-intensive methods of using yeast or bacteria, offering a more cost-effective and environmentally sustainable alternative for producing proteins of medical and industrial significance.
How much funding has Loopworm raised?
Loopworm has raised a total of $10M across 3 funding rounds:
Angel/Seed
$3.4M
Angel/Seed
$3.4M
Other Financing Round
$3.2M
Angel/Seed (2022): $3.4M, investors not publicly disclosed
Angel/Seed (2022): $3.4M led by WaterBridge Ventures and Omnivore
Other Financing Round (2025): $3.2M supported by WaterBridge Ventures
Key Investors in Loopworm
WaterBridge Ventures
WaterBridge Ventures is a venture capital firm dedicated to helping entrepreneurs build generational companies across various sectors, with a focus on backing contrarian founders and pioneering global product teams.
Omnivore
Omnivore is a venture capital firm that invests in startups developing technologies for food, agriculture, and the rural economy, focusing on improving the lives of smallholder farmers.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Loopworm?
With the successful closure of this latest funding round, Loopworm is poised to accelerate the commercialization of its recombinant protein platform. The strategic focus will likely shift toward scaling production capacity and refining the genetic engineering processes that allow silkworms to function as efficient, scalable bioreactors. As the company moves deeper into the industrial biotechnology space, it will face the challenge of maintaining cost-competitiveness while navigating the regulatory landscapes associated with recombinant protein production. Investors will be closely monitoring the firm's ability to transition from pilot-scale success to full-scale industrial deployment, a move that could fundamentally disrupt the current supply chain for high-value proteins.
See full Loopworm company page
